I. Synthetic polymer-based anticancer prodrugs Jindrich Kopecek (Departments of Pharmaceutics and Pharmaceutical Chemistry and of Bioengineering, University of Utah, Salt Lake City, Utah 84112) HPMA-anticancer drug conjugates Richard B. Greenwald (Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey 00854) Poly(ethylene glycol)-anticancer drug conjugates Chun Li (Department of Experimental Diagnostic Imaging, Box 59, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA) Poly(L-glutamic acid)-anticancer drug conjugates II. Natural polymer-based anticancer prodrugs Felix Kratz (Department of Medical Oncology, Clinical Research, Tumor Biology Center, Breisacher Strasse 117, D-79106 Freiburg, Federal Republic of Germany) Protein-based anticancer conjugates Andrew V. Schally (Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana) Peptide and peptide hormone anticancer therapeutics Yoshiharu Machida (Department of Drug Delivery Research, Hoshi University; 2--4--41 Ebara, Shinagawa-ku, Tokyo 142--8501, Japan) Chitosan and other polysaccharide anticancer conjugates III. Antibody-directed cancer therapy John R. Desjarlais Xencor, Inc. CA 91016, United States Engineering of antitumor antibodies Victor S. Goldmacher (ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA) Antibody-anticancer drug conjugates David M. Goldenberg (Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA.) Immunoconjugate and radioimmunoconjugate anticancer therapeutics Kenneth D. Bagshawe (Imperial College London, Department of Medical Oncology, Charing Cross Campus, Fulham Palace Road, London W6 8RF, UK.) Antibody-directed enzyme prodrug anticancer therapeutics Paul M. Harari (University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA.) EGFR-directed monoclonal antibodies Gabriel N. Hortobagyi (Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX. usa) Her2/neu-directed antibodies John M. Kirkwood (Division of Hematology-Oncology, Department of Medicine, Hillman Cancer Center, Pittsburgh, PA 15232) CTLA-4-directed monoclonal antibodies Dario Neri (Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland) Antibodies directed to tumor vasculature IV. Lipid-based anticancer prodrugs L. Harivardhan Reddy, Patrick Couvreur (Physicochimie, Pharmacotechnie et Biopharmacie, Faculty of Pharmacy, Universite Paris-Sud XI, Chatenay-Malabry, France) Lipid-based prodrugs of anti-metabolite anticancer agents Mitsuru Hashida (Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan) Lipid-based prodrugs of non-anti-metabolite anticancer agents V. Macromolecular nucleic acid therapeutics Ernst Wagner (Pharmaceutical Biology-Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universitaet, Butenandtstr. 5--13, D-81377, Muenchen, Germany) Macromolecular nucleic acid therapeutics Uwe Zangemeister-Wittke (Department of Pharmacology, University of Bern, Bern, Switzerland.) Antisense oligonucleotides Brett P. Monia (Isis Pharmaceuticals, California 92008, USA) Therapeutic MicroRNAs Mark A. Behlke (Integrated DNA Technologies Inc., Coralville, IA 52241, USA) Therapeutic siRNAs